Junhang Luo

23PUBLICATIONS
45CO-AUTHORS
Molecular targetsPredictive and prognostic markersMechanobiologyCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Jun 29, 2026
Targeting the ATX-LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways.

|May 06, 2026
Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation.

|Feb 12, 2026
Targeting the C/EBPβ-PRAME-EZH2 complex modulates the Netrin-4/AKT axis to inhibit renal cancer tumorigenesis and metastasis.

Li-Zhen Zhang, Zheng-Kun Zhang, Liang-Min Fu

|Jul 31, 2025
MIAT promotes tumor-infiltrating CD8<sup>+</sup> T-cell exhaustion and malignant progression of renal cell carcinoma via activating JAK3/STAT3 pathway.

Ming-Xiao Zhang, Lan-Yu Jing, Hao-Tian Tan

|Jul 02, 2025
N6-methyladenosine-mediated upregulation of MANF promotes ER stress resistance in renal cell carcinoma.

Junjie Cen, Dongliang Zhao, Xin Shi

|Dec 13, 2024
Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axis.

Anze Yu, Liangmin Fu, Lanyu Jing

Pageof 4

Frequent Collaborators

7 joint publications

Zhenhua Chen

5 joint publications

Wei Chen

3 joint publications

Jian-Ping Guo

3 joint publications

Jun Lu